



Design, synthesis, and biological evaluation of *N*-acetyl-*S*-(*p*-chlorophenylcarbamoyl)cysteine and its analogs as a novel class of anticancer agents

Wei Chen^a, Teresa Seefeldt^a, Alan Young^b, Xiaoying Zhang^{c,d}, Xiangming Guan^{a,*}

^a Department of Pharmaceutical Sciences, South Dakota State University, Brookings, SD 57007, United States

^b Department of Veterinary and Biomedical Science, South Dakota State University, Brookings, SD 57007, United States

^c Shanghai ChemPartner Co., Ltd, Shanghai 201203, China

^d College of Pharmacy, Zhejiang University of Traditional Chinese Medicine, Zhejiang Province 310053, China

ARTICLE INFO

Article history:

Received 22 August 2010

Revised 3 November 2010

Accepted 9 November 2010

Available online 13 November 2010

Keywords:

Anticancer activity

Apoptosis

Cell cycle distribution

Synthesis

Structure activity relationship

ABSTRACT

N-Acetyl-*S*-(*p*-chlorophenylcarbamoyl)cysteine (NACC) was identified as a metabolite of sulofenur. Sulofenur was demonstrated to have broad activity against solid tumors in preclinical studies but exhibited disappointing clinical responses due to its high protein binding related adverse effects. NACC exhibited low protein binding and excellent activity against a sulofenur sensitive human colon cancer cell line. In this study, analogs of NACC were synthesized and evaluated with four human cancer cell lines. Two of the NACC analogs showed excellent activity against two human melanoma cell lines, while NACC remains the most potent of the series. All three compounds were more potent than dacarbazine, which is used extensively in treating melanoma. NACC was shown to induce apoptosis without affecting the cell cycle. Further, NACC exhibited low toxicity against monkey kidney cells. The selective anticancer activity, low toxicity, an unknown yet but unique anticancer mechanism and ready obtainability through synthesis make NACC and its analogs promising anticancer agents.

© 2010 Elsevier Ltd. All rights reserved.

1. Introduction

Following heart disease, cancer is the second leading cause of death in the developed world.¹ For the majority of cancers, chemotherapy, either alone or as an adjunct to radiotherapy or surgery, remains the treatment of choice. Most of the anticancer agents used in clinical practice are broadly acting cytotoxic drugs. These agents impact structure and function of the rapidly proliferating cancer cells and will often arrest the cell cycle in a specific phase depending on the mechanism of action of the agent. Unfortunately, they also lack specificity and produce adverse effects related to the impact on rapidly dividing noncancerous cells.^{2,3} Discovery of more specific anticancer agents in order to improve efficacy and decrease the adverse effect potential is one of the goals in developing new anticancer drugs. Another major goal for developing new

anticancer agents is to overcome cancer resistance to drug treatment that has made many of the currently available chemotherapeutic agents ineffective.⁴


Sulofenur (LY 186641, Fig. 1), a diarylsulfonylurea developed in Lilly Research Laboratories, has been reported to exhibit broad spectrum activity against murine solid tumors and human tumor xenografts.⁵ Sulofenur is also effective against childhood rhabdomyosarcoma.⁶ It has undergone clinical evaluation in lung, breast, colon, ovarian, pancreatic, renal, and gastric cancers.⁵ However, due to its high protein binding, high dosages of sulofenur were required for clinical responses. As a consequence, hemolytic anemia and methemoglobinemia were observed with sulofenur in clinical trials.^{7,8}

In our earlier study of sulofenur metabolism in rats, it was found that the mercapturic acid conjugate of sulofenur, *N*-acetyl-*S*-(*p*-chlorophenylcarbamoyl)cysteine (NACC, Fig. 2), had much lower protein binding and exhibited anticancer activity that was comparable to sulofenur against one sulofenur sensitive human colon cancer cell line (GC₃/c1).⁹ Encouraged by the low protein binding, significant anticancer activity, and ready obtainability through a one-step synthesis, we designed and prepared a series of analogs of NACC in an effort to search for a novel class of anticancer agents. Seventeen analogs (Fig. 2) of NACC were prepared, and their anticancer activities were evaluated against three different human cancer cell lines: UACC-62, GC₃/c1, and OVCAR-3

Abbreviations: TFA, trifluoroacetic acid; BSA, bovine serum albumin; FBS, fetal bovine serum; DMSO, dimethyl sulfoxide; DPBS, Dulbecco's phosphate buffered saline; EWG, electron withdrawing group; EDG, electron donating group; HPLC, high performance liquid chromatography; IC₅₀, concentration that produces 50% cell growth inhibition; NAC, *N*-acetyl-L-cysteine; MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide); PBS, phosphate buffered saline; PI, propidium iodide; PS, phosphatidylserine; THF, tetrahydrofuran.

* Corresponding author. Tel.: +1 605 688 5314; fax: +1 605 688 5993.

E-mail addresses: Wei.Chen@sdstate.edu (W. Chen), Teresa.Seefeldt@sdstate.edu (T. Seefeldt), Alan.Young@sdstate.edu (A. Young), xiaoying.zhang@live.com (X. Zhang), Xiangming.Guan@sdstate.edu (X. Guan).



Scheme 1. Synthesis of NACC and its analogs.

Table 1

Determination of in vitro cytotoxicity of NACC and its analogs against various human cancer cell lines

Compounds	IC ₅₀ ^a (μM)			
	UACC-62	GC3/c1	OVCAR-3	SK-MEL-2
NACC	0.024 ± 0.01	8.13 ± 4.07	>200	0.008 ± 0.001
1	0.036 ± 0.023	114.49 ± 1.21	>200	0.430 ± 0.230
2	>200	>200	>200	N.D.
3	>200	>200	>200	N.D.
4	>200	>200	>200	N.D.
5	>200	>200	>200	N.D.
6	>200	>200	>200	N.D.
7	0.32 ± 0.11	63.47 ± 1.27	>200	0.120 ± 0.030
8	>200	>200	>200	N.D.
9	46.16 ± 2.61	>200	>200	N.D.
10	>200	>200	>200	N.D.
11	>200	>200	>200	N.D.
12	>200	>200	>200	N.D.
13	75.23 ± 4.80	>200	>200	N.D.
14	>200	>200	>200	N.D.
15	>200	>200	>200	N.D.
16	>200	>200	>200	N.D.
17	125.00 ± 5.00	178.33 ± 7.64	153.33 ± 15.28	N.D.
Dacarbazine	11.83 ± 1.03	7.67 ± 2.39	17.67 ± 1.70	120.00 ± 75.5

^a Cells were treated with a compound for 6 days. Cell survival rates were determined by the MTT assay. IC₅₀ values were derived from dose–response curves and are presented as the mean ± SD of three independent experiments. N.D.: not determined.

icant activity demonstrating the selectivity of NACC and its analogs against specific cancers. The selectivity was further confirmed by screening of NACC against other human cancer cell lines that included PC-3 (human prostate cancer), NCI-H226 (human lung cancer), UO-31 (human renal cancer), and A431 (human skin cancer). Poor activities were observed (unpublished data from this laboratory). Since NACC was the most potent anticancer agent of the series, the toxicity of NACC against normal cells was evaluated with CV-1 cells. The IC₅₀ value of NACC against CV-1 cells was determined to be 521.67 ± 7.64 μM demonstrating that NACC exhibited low toxicity toward a normal cell line. Therefore, NACC exhibits not only high selectivity against different cancers but also high selectivity between cancer cells and normal cells.

The selective activity of NACC and its analogs against human melanoma cells is encouraging. Malignant melanoma is an aggressive, therapy-resistant malignancy of melanocytes.¹¹ The incidence of melanoma has been increasing dramatically worldwide in the last few decades.^{11–14} Early-stage melanoma is curable, but advanced, metastatic melanoma is almost uniformly fatal.¹⁵ In most cases, primary surgery excision remains the mainstay in the treatment of malignant melanoma. Early diagnosis combined with appropriate surgical therapy is the only curative treatment.^{16,17} Single-agent or combination chemotherapies have not made a major impact on metastatic melanoma, and complete or durable responses are rare. Dacarbazine remains the only ‘standard’ agent for melanoma chemotherapy¹⁸ and is the only small molecule drug approved by the US Food and Drug Administration (FDA) for the treatment of melanoma. However, it has a response rate of only

10–20%, and complete or durable responses are much lower. Other chemotherapy agents which have been used in the treatment of melanoma with activity similar to dacarbazine include platinum compounds, vinca alkaloids, nitrosoureas, and taxanes. These drugs have not improved clinical outcome.¹³ Therefore, compounds with selective activity against melanoma are of therapeutic potential.

3.3. Structure activity relationship

The anticancer activity screening in UACC-62 cells (Table 1) revealed that the most potent compounds appear to be from the *para*-substituted derivatives. Any substitution at *meta* or *ortho*-position resulted in the loss of activity. Among the *para*-substituted derivatives, 4-halogenated analogs appear to be the most potent with NACC, analog **1** and analog **7** found to be more potent than dacarbazine, respectively. The effect of the substituents does not appear to be caused by the electronic effect of the substituent since moving the chloro or fluoro from the *para*-position to *ortho*-position (NACC vs analog **12** or analog **1** vs analog **6**), which does not significantly affect the aromatic ring electron density, caused a loss of activity. This notion is further supported by the fact that when compared with NACC, both analog **1** and analog **13**, one with a more electron withdrawing group (*p*-F) and one with a more electron donating group (*p*-OMe), exhibited lower activity indicating a decrease or increase in aromatic ring electron density is not correlated with the anticancer activity. Further, none of the analogs with EDGs (analog **3**, **4**, and **8**) or EWGs (analog **5**, **10**, **12**, **15**, and **16**) at positions other than *para* are active, again showing no correlation between the aromatic ring electron density and anticancer activity. Therefore, it is concluded that the effect of the substituent at the *para*-position is likely to be related to the size of the substituent, with small substituents (Cl or F) being more active. It is interesting that the unsubstituted compound (analog **17**) exhibited no significant activity suggesting that there is an interaction between the *para* substituent and the target.

When the thiocarbamoyl group is separated from the aromatic ring by a methylene group as shown in analogs **11** and **16**, the compounds lost activity indicating that the *p*– π conjugation between the aromatic ring and the thiocarbamoyl group might be needed for the activity, or the increased distance between the aromatic ring and the thiocarbamoyl group by insertion of a methylene group might be detrimental, or both might be essential for the activity.

3.4. Solubility determination of the active compounds

To assess whether NACC, compounds **1** and **7** exhibit drugable physicochemical properties, their solubility in both organic phase (ethyl acetate) and aqueous phase (0.1 M, pH 7.4 phosphate buffer) was determined. These compounds exhibit good solubility in both organic phase and aqueous phase with the solubility in ethyl acetate 721, 388, and 50 mg/mL and in the buffer 26, 26, and 24 mg/mL, respectively, for NACC, compounds **1** and **7**.

3.5. Determination of protein binding by equilibrium dialysis

Sulofenur failed in clinical trials due to its high protein binding (greater than 99%) associated hemolytic anemia and methemoglobinemia side effects.^{7,8} The protein binding for compounds **1** and **7** was determined to be 67% and 82%, respectively, much lower than sulofenur but similar to NACC (84%) which was reported earlier.⁹

3.6. Analysis of cellular DNA content by flow cytometry

We further investigated the mechanism of the cancer growth inhibition by NACC and its analogs. Since NACC was the most

potent of the series, it was selected for the investigation. The effects of NACC on the cell cycle distribution were studied with UACC-62 and GC₃/c1 cells by flow cytometric analysis of cellular DNA content using propidium iodide (PI) staining. To be consistent with the cytotoxicity evaluation experiment, UACC-62 and GC₃/c1 cells were treated with NACC for 6 days. After the treatment, only attached cells were collected, and intracellular DNA content was determined. As shown in Figure 3A, no change in cell cycle distribution was observed after UACC-62 cells were treated with NACC (0.01–1 μ M). Similar results were obtained with GC₃/c1 cells (Fig. 3B). The effect of NACC on the cell cycle is interesting since diarylsulfonylureas were also reported to be non-cell cycle specific. A lack of effects on the cell cycle distinguishes diarylsulfonylureas from other conventional anticancer agents that can arrest cells at a specific phase, mostly at the G₁/S or G₂/M boundaries.¹⁹ It is not clear whether it is this property that makes diarylsulfonylureas lack toxicity to proliferating normal cells, a phenomenon also observed with NACC.

3.7. Apoptosis assay by flow cytometry

To further investigate the mechanism of action, the effect of NACC on cell apoptosis was conducted with UACC-62 cells. An apoptotic event is marked by the translocation of phosphatidylserine (PS) from the inner layer to the outer layer of the cell membrane. The translocated PS can be detected using fluorescein-labeled annexin V, a Ca²⁺-dependent phospholipid-binding protein with high affinity to PS. Combined with PI which stains nucleic acids in dead cells, the percentage of the cell population undergoing apoptosis can be determined. After UACC-62 cells were treated

with NACC for 6 days, both adherent and suspended cells were collected and analyzed using flow cytometry. As demonstrated in Figure 4A, NACC induced significant apoptosis in UACC-62 cells. It is interesting that more late apoptotic cells (area b) were observed compared to cells in early apoptosis (area a). This might be due to the 6-day treatment in which the induced apoptotic cells were more in the late stage of apoptosis at the end of the 6-day treatment. Figure 4B provides a quantitative presentation of the apoptotic cells. It shows that NACC induced apoptosis in UACC-62 cells in a concentration dependent manner in the concentration range of 0.1–1 μ M. However, when the concentration exceeds 1 μ M, no further increase in apoptosis was observed (Fig. 4B). It is likely that at high concentrations, NACC may induce cell death through a mechanism other than apoptosis.

4. Conclusions

In this study, NACC and its seventeen analogs were synthesized through a one-step reaction. Based on the IC₅₀ values, NACC remains the most potent compound of the series. NACC also exhibited low toxicity to noncancerous cells. The low toxicity and its impressive activity against UACC-62 and SK-MEL-2 cells suggest the potential of this class of compounds in the treatment of melanoma. The non-cell cycle specific cell growth inhibition is another unique feature of this class of compounds since most conventional anticancer agents achieve their action through affecting the cell cycle. NACC also induced significant apoptosis in UACC-62 cells. Additionally, NACC and its analogs exhibit excellent physicochemical and pharmaceutical properties with low protein binding and good solubility in both organic and aqueous solutions. Further




Figure 3. Effect of NACC on cell cycle distribution in UACC-62 cells (A) and GC₃/c1 cells (B). UACC-62 cells and GC₃/c1 cells were treated with different concentrations of NACC for 6 days. After staining with PI, cell cycle distribution was analyzed using a flow cytometer. Results are presented as the mean \pm SD of three independent experiments.




Figure 4. Effect of NACC on induction of apoptosis in UACC-62 cells. UACC-62 cells were treated with different concentrations of NACC for 6 days. After staining with annexin V and PI, apoptotic cells were analyzed by flow cytometry. The total percentage of apoptotic cells is the sum of early apoptotic cells (Graph A, area a) and late apoptotic cells (Graph A, area b). Graph A presents apoptotic histograms derived from one of the three independent experiments. Graph B presents the summarized data. Results are presented as the mean \pm SD of three independent experiments. * indicates statistical significance ($P < 0.05$) in NACC treated groups as compared to the control.

investigation of NACC and its analogs against melanoma *in vivo* is needed to evaluate their potential in the treatment of melanoma.

5. Experimental section

5.1. Chemistry

5.1.1. General

All chemicals and reagents purchased from commercial sources were used as received. Reactions were monitored by thin layer chromatography (TLC) on prepared silica gel plates with UV indicator. Column chromatography was performed with 40 μ m average particle diameter silica gel. Yields were calculated based on purified products and not optimized. All final products had a purity of $>95\%$ determined by two HPLC methods. Both HPLC methods used Adsorbosil analytical C18 column (3.2 mm \times 250 mm, 5 μ m) with analytes being monitored at 254 nm and a flow rate of 0.5 mL/min. HPLC method A employed a gradient of solvent A [0.1% trifluoroacetic acid (TFA) aqueous solution] and solvent B (acetonitrile) with solvent B being increased from 5% to 80% in 15 min and held for an additional 10 min. HPLC method B employed a gradient of solvent A (0.1% TFA aqueous solution) and solvent B (methanol) with solvent B being increased from 5%

to 80% in 10 min and held for an additional 15 min. Melting points were determined on a Büchi melting point apparatus. IR absorptions were recorded on a Nicolet 380 ATR-FTIR instrument and values are reported in cm^{-1} . All ^1H and ^{13}C NMR spectra were recorded on a Bruker Avance 400 MHz instrument. Chemical shifts are reported as δ values (ppm) downfield from TMS and all J values are in Hertz. The following NMR abbreviations are used: br (broad), s (singlet), d (doublet), dd (doublet of doublets), m (multiplet). Mass spectra were obtained on a Finnigan MAT Navigator mass spectrometer.

5.1.2. General procedure for the preparation of NACC and its analogs (1–17)

NACC and its seventeen analogs were synthesized through a one-step reaction of an isocyanate with NAC (1.1:1, molar ratio) following a reported procedure with modification (Scheme 1).⁹ Briefly, an isocyanate (11 mmol) in 10 mL of tetrahydrofuran (THF) was added dropwise through an addition funnel under argon to a solution of NAC (10 mmol) in a saturated NaHCO_3 solution (20 mL) at room temperature. After 15 min stirring at room temperature, the mixture was filtered and solid was discarded. THF was removed by a rotary evaporator and the aqueous layer was washed twice with ethyl acetate to remove non-acidic organic

by-products. The aqueous solution was then acidified with HCl to pH ~1 over ice followed by extraction with ethyl acetate. The combined ethyl acetate extracts were dried over MgSO_4 , filtered, concentrated, and purified by flash column chromatography (silica gel, EtOAc/hexane, gradient). The purified product was dissolved in acetonitrile and water (1:1, v/v) and dried by lyophilization. Due to the instabilities of compounds **16** and **17** in ethyl acetate, the reaction solutions of compounds **16** and **17** were lyophilized followed by extraction with methanol. The crude products of **16** and **17** were purified by flash column chromatography (silica gel, methanol/methylene dichloride).

5.1.2.1. N-Acetyl-S-(p-chlorophenylcarbamoyl)cysteine (NACC). The title compound was obtained from the reaction of NAC and *p*-chlorophenylisocyanate in 80% yield. The spectral data were identical to that reported earlier.⁹

5.1.2.2. N-Acetyl-S-(p-fluorophenylcarbamoyl)cysteine (1). The title compound was obtained from the reaction of NAC with *p*-fluorophenylisocyanate by following the procedure as described in the method. Yield, 50%; white solid, mp 71–74 °C. ^1H NMR (acetone- d_6): δ 1.98 (s, 3H, CH_3), 3.29 (dd, J = 7.6, 14.0 Hz, 1H, CH_2), 3.58 (dd, J = 4.8, 14.0 Hz, 1H, CH_2), 4.73 (m, 1H, NCH), 6.95–7.14 (m, 2H, phenyl), 7.66–7.45 (m, J = 9.2 Hz, 3H, phenyl, NH), 9.50 (s). ^{13}C NMR (acetone- d_6): δ 170.7, 169.8, 164.3, 135.0, 120.7, 115.1, 114.9, 52.3, 30.7, 21.5. MS: 301 (MH^+). IR (cm^{-1}): 3277, 1724, 1655, 1618, 1536, 1507.

5.1.2.3. N-Acetyl-S-(naphthalen-1-ylcarbamoyl)cysteine (2). The title compound was obtained from the reaction of NAC with 1-isocyanatonaphthalene following the procedure as described in the method. Yield, 87%; white solid, mp 128–131 °C. ^1H NMR ($\text{DMSO}-d_6$): δ 1.87 (s, 3H, CH_3), 3.08 (dd, J = 8.4, 13.6 Hz, 1H, CH_2), 3.42 (dd, J = 4.8, 13.6 Hz, 1H, CH_2), 4.42 (m, 1H, NCH), 7.60–7.46 (m, 4H, phenyl), 7.82 (d, J = 8.0 Hz, 1H, phenyl), 8.02–7.92 (m, 2H, phenyl), 8.29 (d, J = 8.0 Hz, 1H, NH), 10.36 (s, 1H). ^{13}C NMR ($\text{DMSO}-d_6$): δ 170.8, 168.1, 164.8, 132.6, 132.1, 127.3, 126.9, 125.1, 125.0, 124.4, 121.9, 121.7, 116.9, 51.1, 29.7, 21.3. MS: 333 (MH^+). IR (cm^{-1}): 3265, 1724, 1650, 1524, 1495.

5.1.2.4. N-Acetyl-S-(o-methylsulfanylphenylcarbamoyl)cysteine (3). The title compound was obtained from the reaction of NAC with *o*-methylsulfanylphenylisocyanate. Yield, 69%; white solid, mp 55–60 °C. ^1H NMR (acetone- d_6): δ 1.96 (s, 3H, CH_3), δ 2.43 (s, 3H, CH_3), 3.33–3.23 (m, 1H, CH_2), 3.59–3.49 (m, 1H, CH_2), 4.71 (m, 1H, NCH), 7.33–7.15 (m, 2H, phenyl), 7.55–7.38 (m, 2H, phenyl), 7.69 (d, J = 6.8 Hz, 1H, NH), 8.75 (s, 1H, NH). ^{13}C NMR (acetone- d_6): δ 172.3, 171.2, 167.0, 137.5, 130.6, 128.0, 127.5, 125.9, 125.8, 53.9, 32.4, 23.1, 17.4. MS: 329 (MH^+). IR (cm^{-1}): 3291, 1732, 1642, 1499.

5.1.2.5. N-Acetyl-S-(o-methoxyphenylcarbamoyl)cysteine (4). The title compound was obtained from the reaction of NAC with *o*-methoxyphenylisocyanate. Yield, 87%; white solid, mp 62–65 °C. ^1H NMR (acetone- d_6): δ 1.96 (s, 3H, CH_3), 3.25–3.33 (m, 1H, CH_2), 3.60–3.53 (m, 1H, CH_2), δ 3.86 (s, 3H, OCH_3), 4.71 (m, 1H, NCH), 7.11–6.89 (m, 3H, phenyl), 7.54 (d, J = 5.2 Hz, 1H, phenyl), 8.01 (d, J = 8.0 Hz, 1H, NH), 8.60 (s, 1H, NH). ^{13}C NMR (acetone- d_6): δ 170.7, 169.5, 164.3, 148.8, 127.2, 124.2, 120.6, 120.2, 110.5, 55.0, 52.2, 30.8, 21.5. MS: 313 (MH^+). IR (cm^{-1}): 3319, 1733, 1652, 1602, 1518.

5.1.2.6. N-Acetyl-S-(o-chloro-p-nitrophenylcarbamoyl)cysteine (5). The title compound was obtained from the reaction of NAC with *o*-chloro-*p*-nitrophenylisocyanate. Yield, 31%; white solid, mp 56–59 °C. ^1H NMR (acetone- d_6): δ 1.98 (s, 3H, CH_3), 3.33 (dd,

J = 7.6, 14.0 Hz, 1H, CH_2), 3.64 (dd, J = 4.8, 14.0 Hz, 1H, CH_2), 4.74 (m, 1H, NCH), 7.66–7.38 (m, 2H, phenyl), 8.39–8.15 (m, 3H, phenyl, 2NH), 9.33 (s, 1H, OH). ^{13}C NMR (acetone- d_6): δ 170.7, 169.5, 166.2, 143.3, 140.4, 124.7, 123.5, 122.9, 122.4, 51.8, 21.2, 21.5. MS: 362 (MH^+). IR (cm^{-1}): 3342, 1587, 1537, 1507.

5.1.2.7. N-Acetyl-S-(o-fluorophenylcarbamoyl)cysteine (6). The title compound was obtained from the reaction of NAC with *o*-fluorophenylisocyanate. Yield, 61%; white solid, mp 65–70 °C. ^1H NMR (acetone- d_6): δ 1.97 (s, 3H, CH_3), 3.34–3.23 (m, 1H, CH_2), 3.62–3.51 (m, 1H, CH_2), 4.73 (m, 1H, NCH), 7.21–7.12 (m, 3H, phenyl), 7.59–7.46 (m, 1H, phenyl), 7.98–7.86 (m, 1H, NH), 9.25 (s, 1H, NH). ^{13}C NMR (acetone- d_6): δ 170.7, 169.6, 165.2, 154.6, 125.9, 125.8, 125.2, 124.1, 115.0, 52.2, 31.8, 21.5. MS: 301 (MH^+). IR (cm^{-1}): 3269, 1650, 1614, 1524.

5.1.2.8. N-Acetyl-S-(p-bromophenylcarbamoyl)cysteine (7). The title compound was obtained from the reaction of NAC with *p*-bromophenylisocyanate. Yield, 93%; white solid, mp 80–84 °C. ^1H NMR (acetone- d_6): δ 1.97 (s, 3H, CH_3), 3.33–3.23 (m, 1H, CH_2), 3.62–3.53 (m, 1H, CH_2), 4.73 (m, 1H, NCH), 7.67–7.39 (m, 5H, phenyl, NH), 9.25 (s, 1H, NH). ^{13}C NMR (acetone- d_6): δ 170.7, 169.7, 164.4, 138.0, 131.5, 120.6, 115.2, 52.2, 30.7, 21.5. MS: 363 (MH^+). IR (cm^{-1}): 3281, 1659, 1589, 1524, 1483.

5.1.2.9. N-Acetyl-S-(2,5-dimethoxyphenylcarbamoyl)cysteine (8). The title compound was obtained from the reaction of NAC with 2,5-dimethoxyphenylisocyanate. Yield, 83%; white solid, mp 144–146 °C. ^1H NMR ($\text{DMSO}-d_6$): δ 1.86 (s, 3H, CH_3), 3.02 (dd, J = 8.8, 13.8 Hz, 1H, CH_2), 3.37 (dd, J = 4.8, 13.8 Hz, 1H, CH_2), 4.36 (m, 1H, NCH), 6.68 (dd, J = 3.2, 9.0 Hz, 1H, phenyl), 6.96 (d, J = 8.8 Hz, 1H, phenyl), 7.31 (s, 1H, phenyl), 8.29 (d, J = 8.0 Hz, 1H, NH), 9.53 (s, 1H, NH). ^{13}C NMR ($\text{DMSO}-d_6$): δ 170.8, 168.2, 163.7, 151.6, 143.5, 126.2, 123.2, 11.2, 108.3, 55.0, 54.2, 51.1, 29.5, 21.2. MS: 343 (MH^+). IR (cm^{-1}): 3322, 1687, 1605, 1516.

5.1.2.10. N-Acetyl-S-(p-iodophenylcarbamoyl)cysteine (9). The title compound was obtained from the reaction of NAC with *p*-iodophenylisocyanate. Yield, 75%; white solid, mp 92–95 °C. ^1H NMR (acetone- d_6): δ 1.97 (s, 3H, CH_3), 3.29 (dd, J = 7.6, 14.0 Hz, 1H, CH_2), 3.58 (dd, J = 4.4, 14.0 Hz, 1H, CH_2), 4.73 (m, 1H, NCH), 7.33 (d, J = 8.4 Hz, 2H, phenyl), 7.55 (d, J = 7.6 Hz, 1H, NH), 7.66 (d, J = 8.4 Hz, 2H, phenyl), 9.55 (s, 1H, NH). ^{13}C NMR (acetone- d_6): δ 170.7, 169.6, 164.4, 138.6, 137.5, 120.9, 85.8, 52.2, 30.8, 21.5. MS: 409 (MH^+). IR (cm^{-1}): 3284, 1659, 1581, 1520.

5.1.2.11. N-Acetyl-S-(o-nitro-p-trifluoromethylphenylcarbamoyl)cysteine (10). The title compound was obtained from the reaction of NAC with *o*-nitro-*p*-trifluoromethylphenylisocyanate. Yield, 52%; light yellow solid, mp 69–72 °C. ^1H NMR ($\text{DMSO}-d_6$): δ 1.87 (s, 3H, CH_3), 3.11 (dd, J = 8.8, 13.4 Hz, 1H, CH_2), 3.41 (dd, J = 5.2, 13.6 Hz, 1H, CH_2), 4.37 (m, 1H, NCH), 7.82 (d, J = 8.4 Hz, 1H, phenyl), 8.09 (dd, J = 2.0, 8.8 Hz, 1H, phenyl), 8.34–8.27 (m, 2H, phenyl, NH), 11.05 (br, 1H). ^{13}C NMR ($\text{DMSO}-d_6$): δ 170.9, 168.2, 165.0, 140.4, 133.0, 129.5, 124.6, 121.6, 120.5, 50.8, 29.8, 21.2, 19.9. MS: 396 (MH^+). IR (cm^{-1}): 3309, 1626, 1581, 1512.

5.1.2.12. N-Acetyl-S-(o-methoxybenzylcarbamoyl)cysteine (11). The title compound was obtained from the reaction of NAC with *o*-methoxybenzylisocyanate. Yield, 61%; white solid, mp 63–65 °C. ^1H NMR (acetone- d_6): δ 1.90 (s, 3H, CH_3), 3.23 (dd, J = 8.4, 14.0 Hz, 1H, CH_2), 3.46 (dd, J = 4.4, 14.0 Hz, 1H, CH_2), 3.84 (s, 3H, OCH_3), 4.43 (m, 2H, CH_2), 4.61 (m, 1H, NCH), 6.99–6.86 (m, 2H, phenyl), 7.29–7.21 (m, 2H, phenyl), 7.46 (d, J = 7.2 Hz, 1H, NH), 7.67 (s, 1H, NH). ^{13}C NMR (acetone- d_6): δ 170.7, 169.6, 165.8, 156.9, 128.2, 126.0, 120.0, 110.0, 54.5, 52.8, 39.7, 30.4, 21.5. MS: 327 (MH^+). IR (cm^{-1}): 3311, 1654, 1493.

5.1.2.13. N-Acetyl-S-(*o*-chlorophenylcarbamoyl)cysteine (12). The title compound was obtained from the reaction of NAC with *o*-chlorophenylisocyanate. Yield, 85%; white solid, mp 64–66 °C. ¹H NMR (acetone-*d*₆): δ 2.00 (s, 3H, CH₃), 3.30 (dd, *J* = 7.6, 14.0 Hz, 1H, CH₂), 3.58 (dd, *J* = 4.4, 14.0 Hz, 1H, CH₂), 4.73 (m, 1H, NCH), 7.24–7.17 (m, 1H, phenyl), 7.38–7.31 (m, 1H, phenyl), 7.47 (dd, *J* = 1.6, 8.0 Hz, 1H, phenyl), 7.56 (d, *J* = 8.0 Hz, 1H, NH), 7.87 (dd, *J* = 8.2, 1.6 Hz, 1H, NH), 8.95 (s, 1H, COOH). ¹³C NMR (acetone-*d*₆): δ 170.7, 169.6, 165.5, 134.5, 129.3, 127.3, 126.1, 125.8, 125.1, 52.2, 30.9, 21.5. MS: 317 (MH⁺). IR (cm^{−1}): 3330, 1646, 1589, 1512.

5.1.2.14. N-Acetyl-S-(*p*-methoxyphenylcarbamoyl)cysteine (13). The title compound was obtained from the reaction of NAC with *p*-methoxyphenylisocyanate. Yield, 85%; white solid, mp 69–72 °C. ¹H NMR (acetone-*d*₆): δ 1.93 (s, 3H, CH₃), 3.26 (dd, *J* = 7.6, 13.7 Hz, 1H, CH₂), 3.54 (dd, *J* = 4.6, 13.7 Hz, 1H, CH₂), 3.76 (s, 3H, OCH₃), 4.66 (m, 1H, NCH), 6.88 (d, *J* = 9.3 Hz, 2H, phenyl), 7.47 (d, *J* = 9.3 Hz, 2H, phenyl). ¹³C NMR (acetone-*d*₆): δ 168.8, 167.9, 167.8, 162.1, 154.1, 129.8, 118.8, 57.4, 50.5, 28.7, 19.5. MS: 313 (MH⁺). IR (cm^{−1}): 3271 (br), 1729, 1656, 1509.

5.1.2.15. N-Acetyl-S-(3,5-dichlorophenylcarbamoyl)cysteine (14). The title compound was obtained from the reaction of NAC with 3,5-dichlorophenylisocyanate. Yield, 85%; white solid, mp 93–95 °C. ¹H NMR (acetone-*d*₆): δ 1.93 (s, 3H, CH₃), 3.27 (dd, *J* = 7.6, 14.0 Hz, 1H, CH₂), 3.59 (dd, *J* = 4.4, 14.0 Hz, 1H, CH₂), 4.69 (m, 1H, NCH), 7.16 (t, *J* = 1.8 Hz, 1H, phenyl), 7.62 (d, *J* = 1.8 Hz, 2H, phenyl). ¹³C NMR (acetone-*d*₆): δ 168.7, 167.5, 163.2, 138.9, 132.6, 120.8, 115.0, 57.4, 49.9, 19.5. MS: 353 (MH⁺). IR (cm^{−1}): 3257 (br), 1728, 1695, 1658, 1536.

5.1.2.16. N-Acetyl-S-(3-chlorophenylcarbamoyl)cysteine (15). The title compound was obtained from the reaction of NAC with 3-chlorophenylisocyanate. Yield, 85%; white solid, mp 96–100 °C. ¹H NMR (acetone-*d*₆): δ 1.93 (s, 3H, CH₃), 3.28 (dd, *J* = 7.8, 14.0 Hz, 1H, CH₂), 3.57 (dd, *J* = 4.6, 14.0 Hz, 1H, CH₂), 4.71 (m, 1H, NCH), 7.10 (m, 1H, phenyl), 7.40 (m, 3H, phenyl), 7.75 (m, 1H, phenyl). ¹³C NMR (acetone-*d*₆): δ 168.8, 168.5, 162.8, 138.0, 131.8, 128.1, 121.2, 116.7, 115.1, 50.2, 28.8, 19.5. MS: 317 (MH⁺). IR (cm^{−1}): 3271 (br), 1729, 1660, 1534.

5.1.2.17. N-Acetyl-S-(4-chlorobenzylcarbamoyl)cysteine (16). The title compound was obtained from the reaction of NAC with 4-chlorobenzylisocyanate. Yield, 44%; white solid, mp 115–119 °C. ¹H NMR (methyl alcohol-*d*₄): δ 1.90 (s, 3H, CH₃), 3.22 (dd, *J* = 8.0, 13.6 Hz, 1H, CH₂), 3.50 (dd, *J* = 4.0, 14.0 Hz, 1H, CH₂), 4.35 (s, 2H, CH₂), 4.42 (m, 1H, NCH), 7.33–7.23 (m, 4H, phenyl). ¹³C NMR (methyl alcohol-*d*₄): δ 176.8, 172.8, 169.8, 132.6, 139.0, 134.0, 130.2, 129.6, 56.6, 45.0, 33.3, 22.9. MS: 331 (MH⁺). IR (cm^{−1}): 2873, 1650, 1602.

5.1.2.18. N-Acetyl-S-(phenylcarbamoyl)cysteine (17). The title compound was obtained from the reaction of NAC with phenylisocyanate. Yield, 10%; light yellow solid, mp 95–98 °C. ¹H NMR (methyl alcohol-*d*₄): δ 1.97 (s, 3H, CH₃), 3.23 (dd, *J* = 8.0, 14.0 Hz, 1H, CH₂), 3.57 (dd, *J* = 4.4, 14.0 Hz, 1H, CH₂), 4.61 (m, 1H, NCH), 7.10–7.02 (m, 1H, phenyl), 7.34–7.24 (m, 2H, phenyl), 7.53–7.44 (m, 2H, phenyl). ¹³C NMR (methyl alcohol-*d*₄): δ 174.4, 173.3, 166.9, 162.5, 140.1, 129.9, 125.0, 120.6, 54.8, 32.3, 22.6. MS: 283 (MH⁺). IR (cm^{−1}): 2359, 1622.

5.2. Biology

5.2.1. Cell lines and culture conditions

UACC-62, OVCAR-3, and SK-MEL-2 cells were obtained from the National Cancer Institute (NCI). CV-1 cells were obtained from American Type Culture Collection (ATCC). GC3/c1 cells were ob-

tained as a kind gift from Dr. Peter J. Houghton of St. Jude Children's Research Hospital. Cells were grown in RPMI 1640 growth medium supplemented with 10% FBS, 100 units/mL of penicillin and 100 µg/mL of streptomycin in a humidified atmosphere containing 5% CO₂ at 37 °C.

5.2.2. In vitro cytotoxicity evaluation

NACC and its analogs were tested in vitro for cytotoxicity against UACC-62, GC3/c1, OVCAR-3, SK-MEL-2, and CV-1 cells in a 96-well plate using the MTT assay to determine cell survival rates. Dacarbazine was chosen as a positive control. In brief, cells (1500, 5000, 2000, 4000, and 500 cells for UACC-62, GC3/c1, OVCAR-3, SK-MEL-2, and CV-1 cells, respectively) were plated into a 96-well plate and allowed to attach for 24 h. After attachment, the medium was replaced with the medium containing variable concentrations of NACC or its analogs. Cells were exposed to the drug for 6 days followed by the MTT assay to determine cell survival rates.

5.2.3. Determination of protein binding by equilibrium dialysis

The protein binding of analog **1** and analog **7** was determined based on a procedure reported earlier for the protein binding determination of NACC.⁹

5.2.4. Analysis of cellular DNA content by flow cytometry

GC3/c1 (0.3 million) or UACC-62 (0.14 million) cells were plated in 75 cm² flasks and were directly treated with 30 mL of medium containing various concentrations of NACC for 6 days. At the end of treatment, adherent cells were harvested by trypsinization and washed twice with ice-cold PBS. One million cells of each sample were fixed with 70% ethanol in DPBS at 4 °C. Fixed cells were then centrifuged (2500 rpm × 5 min) and washed with staining buffer. After the wash, the samples were centrifuged (2500 rpm × 5 min) and the pellets were treated with 100 µL of RNase A (1 mg/mL) for 30 min at 37 °C. After incubation, 900 µL of staining buffer was added to the samples to make up the volume to 1 mL followed by addition of 20 µL of PI (1 mg/mL). The sample was incubated in the dark at room temperature for 30 min and analyzed with BD FACSscan™ flow cytometer using CellQuest software.

5.2.5. Apoptosis assay by flow cytometry

Vybrant Apoptosis Kit 2 (Molecular Probes, Carlsbad, CA) was used to quantitate apoptosis in UACC-62 cells treated with NACC. The kit contains annexin V labeled with green-fluorescent Alexa Fluor 488 and PI. In brief, UACC-62 cells were plated and treated with NACC in a 96-well plate as described above for cytotoxicity activity evaluation. At the end of the treatment, adherent and suspended cells were harvested through trypsinization from the plate and washed twice with ice-cold PBS and then cell pellets were resuspended with annexin-binding buffer to give a final concentration of 1 × 10⁶ cells/mL. Approximately 1 × 10⁵ cells in 100 µL buffer were incubated in the dark with 5 µL of annexin V and 1 µL of the 100 µg/mL PI solutions for 15 min at room temperature. After incubation, 200 µL of annexin-binding buffer was added to each sample, and the samples were analyzed with BD FACSscan flow cytometer.

Acknowledgments

This work was supported by grants from the National Institutes of Health (CA098810-01, CA120062-01) and 2005 Governor Rounds' Individual Research Seed Grant Awards. The authors would like to thank Dr. Peter J. Houghton of St. Jude Children's Research Hospital, Memphis, Tennessee for kindly supplying human colon adenocarcinoma GC3/c1 cells.

References and notes

1. Zhang, J. Y. *Nat. Rev. Drug Disc.* **2002**, *1*, 101.
2. Buolamwini, J. K. *Curr. Opin. Chem. Biol.* **1999**, *3*, 500.
3. MacDonald, V. *Can. Vet. J.* **2009**, *50*, 665.
4. Borowski, E.; Bontemps-Gracz, M. M.; Piwkowska, A. *Acta Biochim. Pol.* **2005**, *52*, 609.
5. Mohamadi, F.; Spees, M. M.; Grindey, G. B. *J. Med. Chem.* **1992**, *35*, 3012.
6. Phelps, P. C.; Jain, P. T.; Berezesky, I. K.; Boder, G. B.; Trump, B. F. *Cancer Lett.* **1995**, *88*, 27.
7. Ehlhardt, W. J. *Drug Metab. Dispos.* **1991**, *19*, 370.
8. Molthrop, D. C., Jr.; Wheeler, R. H.; Hall, K. M.; Prchal, J. T. *Invest. New Drugs* **1994**, *12*, 99.
9. Guan, X.; Hoffman, B. N.; McFarland, D. C.; Gilkerson, K. K.; Dwivedi, C.; Erickson, A. K.; Bebensee, S.; Pellegrini, J. *Drug Metab. Dispos.* **2002**, *30*, 331.
10. Metelmann, H. R.; Von Hoff, D. D. *Int. J. Cell Cloning* **1983**, *1*, 24.
11. Markovic, S. N.; Erickson, L. A.; Rao, R. D.; Weenig, R. H.; Pockaj, B. A.; Bardia, A.; Vachon, C. M.; Schild, S. E.; McWilliams, R. R.; Hand, J. L.; Laman, S. D.; Kottschade, L. A.; Maples, W. J.; Pittelkow, M. R.; Pulido, J. S.; Cameron, J. D.; Creagan, E. T. *Mayo Clin. Proc.* **2007**, *82*, 364.
12. Cornish, D.; Holterhues, C.; van de Poll-Franse, L. V.; Coebergh, J. W.; Nijsten, T. *Ann. Oncol.* **2009**, *20*, vi51.
13. O'Day, S. J.; Kim, C. J.; Reintgen, D. S. *Cancer Control* **2002**, *9*, 31.
14. Hocker, T. L.; Singh, M. K.; Tsao, H. J. *Invest. Dermatol.* **2008**, *128*, 2575.
15. Gogas, H. J.; Kirkwood, J. M.; Sondak, V. K. *Cancer* **2007**, *109*, 455.
16. Testori, A.; Rutkowski, P.; Marsden, J.; Bastholt, L.; Chiarion-Sileni, V.; Hauschild, A.; Eggermont, A. M. *Ann. Oncol.* **2009**, *20*, vi22.
17. Markovic, S. N.; Erickson, L. A.; Rao, R. D.; Weenig, R. H.; Pockaj, B. A.; Bardia, A.; Vachon, C. M.; Schild, S. E.; McWilliams, R. R.; Hand, J. L.; Laman, S. D.; Kottschade, L. A.; Maples, W. J.; Pittelkow, M. R.; Pulido, J. S.; Cameron, J. D.; Creagan, E. T. *Mayo Clin. Proc.* **2007**, *82*, 490.
18. Flaherty, K. T. *Clin. Cancer Res.* **2006**, *12*, 2366s.
19. Shapiro, G. I.; Harper, J. W. *J. Clin. Invest.* **1999**, *104*, 1645.